Human CTLA-4 Antibody New
Human CTLA-4 Antibody Summary
Accession # P16410
Complete Your Research
Complete Your Experiment
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CTLA-4 (Cytotoxic T-lymphocyte Associated protein‑4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41-43 kDa (2) Within the ECD, human CTLA-4 shares 68%, 71% and 83‑86% aa sequence identity with mouse, rat and porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3-5). Isoforms of 56-79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1-2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7-1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11-13).
- Harper, K. et al. (1991) J. Immunol. 147:1037.
- Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
- Magistrelli, G. et al. (1999) Eur. J. Immunol. 29:3596.
- Tector, M. et al. (2009) BMC Immunol. 10:51.
- Oaks, M.K. and K.M. Hallett (2000) J. Immunol. 164:5015.
- Vijayakrishnan, L. et al. (2004) Immunity 20:563.
- Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
- Jansson, A. et al. (2005) J. Immunol 175:1575.
- Darlington, P.J. et al. (2005) J. Immunol. 175:996.
- Platt, A.M. et al. (2010) J. Immunol. 185:1558.
- Wing, K. et al. (2008) Science 322:271.
- Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
- Jain, N. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1524.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CTLA-4 Antibody
There are currently no reviews for this product. Be the first to review Human CTLA-4 Antibody and earn rewards!
Have you used Human CTLA-4 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image